IRIS
ADAMO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.749
EU - Europa 6.054
AS - Asia 1.908
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
SA - Sud America 7
AF - Africa 3
Totale 14.738
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.722
IE - Irlanda 1.623
SE - Svezia 1.590
CN - Cina 996
SG - Singapore 722
IT - Italia 695
UA - Ucraina 483
PL - Polonia 468
DE - Germania 351
FI - Finlandia 260
GB - Regno Unito 216
FR - Francia 172
IN - India 85
BE - Belgio 71
VN - Vietnam 50
AT - Austria 42
CA - Canada 24
RU - Federazione Russa 23
ID - Indonesia 21
CZ - Repubblica Ceca 11
NL - Olanda 9
EU - Europa 8
IR - Iran 8
JP - Giappone 8
ES - Italia 6
AU - Australia 5
HR - Croazia 5
CH - Svizzera 4
HK - Hong Kong 4
LV - Lettonia 4
NO - Norvegia 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AR - Argentina 2
BG - Bulgaria 2
CL - Cile 2
IL - Israele 2
KZ - Kazakistan 2
LT - Lituania 2
LU - Lussemburgo 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
RO - Romania 2
RS - Serbia 2
ZA - Sudafrica 2
AL - Albania 1
BD - Bangladesh 1
BO - Bolivia 1
BR - Brasile 1
CO - Colombia 1
CR - Costa Rica 1
CU - Cuba 1
DK - Danimarca 1
EE - Estonia 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
IQ - Iraq 1
MA - Marocco 1
MM - Myanmar 1
MX - Messico 1
MY - Malesia 1
PH - Filippine 1
SA - Arabia Saudita 1
TR - Turchia 1
Totale 14.738
Salva come PNG Salva come JPEG
Città #
Dublin 1.621
Chandler 1.375
Jacksonville 1.009
Nyköping 847
Singapore 592
Warsaw 465
Beijing 411
Ashburn 351
New York 283
Ann Arbor 277
Princeton 272
Medford 259
Dearborn 250
Cambridge 240
Des Moines 208
Messina 166
Boardman 164
Woodbridge 84
Jinan 83
Brussels 70
Lancaster 70
Wilmington 61
Pune 58
Shenyang 55
Los Angeles 54
San Mateo 53
Dong Ket 46
Nanjing 42
Vienna 40
Tianjin 37
Hebei 34
Zhengzhou 33
Houston 27
Haikou 25
Hangzhou 23
Seattle 23
Helsinki 22
Jakarta 21
Nanchang 21
Changsha 19
Leawood 19
Ningbo 19
Jiaxing 18
Taizhou 18
Guangzhou 17
Milan 16
Taiyuan 16
Hyderabad 15
Washington 15
Fuzhou 14
Grammichele 14
Fort Washington 13
Lanzhou 13
Norwalk 13
Bremen 12
London 12
Rome 12
Santa Clara 11
Augusta 10
Monmouth Junction 9
Toronto 9
Clearwater 8
Falls Church 8
Modica 8
Las Vegas 7
Brno 6
Catania 6
Edinburgh 6
Kunming 6
Ottawa 6
Saint Petersburg 6
Tappahannock 6
Wuhan 6
Ardabil 5
Montréal 5
Shenzhen 5
Auburn Hills 4
Bari 4
Brescia 4
Colombes 4
Hong Kong 4
Kemerovo 4
La Spezia 4
Lappeenranta 4
Mumbai 4
Munich 4
Napoli 4
Olomouc 4
Redwood City 4
Shanghai 4
Tokyo 4
Brockport 3
Frankfurt am Main 3
Hanoi 3
Hefei 3
Madrid 3
Mountain View 3
Novi 3
Novokuznetsk 3
Radomsko 3
Totale 10.267
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 364
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 128
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 122
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 107
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 99
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 96
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 92
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 92
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 89
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study 88
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 87
Intralesional sonographically guided injections of lymphokine- activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: A pilot study 87
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 86
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 84
SPONTANEOUS TRANSFORMATION AND IMMORTALIZATION OF PERITONEAL- MACROPHAGES OF HUMAN-ORIGIN 84
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 83
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 83
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 83
NSCLC and HER2: between lights and shadows 83
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 82
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 82
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 81
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 81
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 81
The Mam-1 GOCSI Trial: a Randomised Trial with Factorial Design of Chemo-Endocrine Adjuvant Treatment in Node-Positive (N+) Early Breast Cancer (EBC). 80
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 80
Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup 80
Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 80
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 79
HER-2 overexpression in advanced node-positive gastric carcinomas: is there any relationship with other clinico-pathological histoprognostic parameters? 78
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 77
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 77
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery 76
[Serum levels of copper and zinc in patients with lung cancer] 76
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 76
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 76
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 75
Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. 74
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 74
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 74
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 74
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 74
I Tumori del coloretto. La chemioterapia della fase avanzata. 73
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives. 73
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 73
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 73
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 73
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 71
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 71
An immunohistochemical investigation of pre-metastatic niche (PMN) in node-negative invasive breast carcinomas 71
The treatment of peritoneal carcinomatosis in elderly patients. 71
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 71
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 71
Detection Of Lynphocytic β - Endorphin In Cancer Patients During Hospedalization And After In Vitro Culture With IL 2. 71
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 70
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 69
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 69
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 69
Safety of Capecitabine plus Bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC) 69
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 69
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 69
Phase II study paclitaxel (PTX) and cisplatin (Cis) in advanced and recurrent head&neck cancer 68
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 68
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 68
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study 67
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 67
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 67
Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. 67
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 67
FCM detection of lymphocytic beta-endorphin in cancer patients during hospitalization and after in vitro culture with IL2 66
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 66
TCC superficiale della vescica: identificazione nel sedimento urinario di mediatori di proliferazione cellulare quali possibili indici di recidiva e progressione neoplastica. 66
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 66
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 65
CyberKnife Radiosurgery Alone or Combined with "Dose Dense" Temozolomide Administration for Recurrent Gliomas. 65
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 65
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 65
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINE + VINORELBINE IN ADVANCED NSCLC EDERLY PATIENTS .PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY(MILES) RANDOMIZED TRIAL 64
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 64
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 64
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 64
Breast. La terapia primaria: stato dell'arte 64
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 64
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 63
Peritoneal carcinomatosis of colorectal origin. 63
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 63
Correction to: Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 63
AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer 62
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 62
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 62
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile 61
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 61
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 61
The treatment of recurrent and metastatic cervical carcinoma. Evaluation of an antiblastic combination of methotrexate-adriamycin-bleomycin (MAB) 61
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 61
Phase III trial comparing 3-6months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: Safety and compliance in the TOSCA trial 61
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 60
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 59
MORPHOLOGICAL, PHENOTYPIC AND KARYOTYPIC CHARACTERIZATION OF A NOVEL NATURAL-KILLER-CELL TARGET - EVIDENCE OF INVOLVEMENT OF MHC CLASS-I MOLECULES IN NK CELL RECOGNITION 59
Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). 59
Totale 7.658
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.659
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.659
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.188 0 0 0 0 0 0 250 239 49 257 330 63
2020/20212.251 224 48 416 221 205 223 115 159 77 238 193 132
2021/20221.776 19 244 30 45 58 16 106 65 15 320 265 593
2022/20235.031 390 493 216 420 382 514 80 329 1.989 19 141 58
2023/20241.304 103 186 70 108 71 498 66 56 5 46 11 84
2024/2025958 66 47 92 316 259 168 10 0 0 0 0 0
Totale 15.023